Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Medina, Alejandro, Puig, Noemi, Flores-Montero, Juan, Jimenez, Cristina, Sarasquete, M.-Eugenia, Garcia-Alvarez, María, Prieto-Conde, Isabel, Chillon, Carmen, Alcoceba, Miguel, Gutierrez, Norma C., Oriol, Albert, Rosinol, Laura, Bladè, Joan, Gironella, Mercedes, Hernandez, Miguel T., Gonzalez-Calle, Veronica, Cedena, Maria-Teresa, Paiva, Bruno, San-Miguel, Jesus F., Lahuerta, Juan-Jose, Mateos, Maria-Victoria, Martinez-Lopez, Joaquin, Orfao, Alberto, Gonzalez, Marcos, Garcia-Sanz, Ramon
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7603393/
https://ncbi.nlm.nih.gov/pubmed/33127891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00377-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars